Miki L. Yamamoto

Miki L. Yamamoto is an accomplished regulatory affairs professional with extensive experience in the biopharmaceutical industry. Currently serving as Senior Vice President and Head of Regulatory Affairs at ArriVent Biopharma since September 2021, Miki previously held similar roles at QED Therapeutics, where significant achievements included leading the regulatory team in securing FDA accelerated approval for Truseltiq. Miki's career also includes consulting work at MLY Associates and roles at IGNYTA, Seragon Pharmaceuticals, and Aragon Pharmaceuticals, all notably acquired by larger pharmaceutical companies. Academic qualifications include a Ph.D. in Biology from the University of California, Berkeley, a B.S. in Genetics and Cell Biology from Washington State University, and a certificate in Clinical Trials Design and Management from San Francisco State University.